ELAN
HealthcareElanco Animal Health Incorporated · Drug Manufacturers - Specialty & Generic · $11B
What is Elanco Animal Health Incorporated?
Elanco Animal Health is a large-cap animal health company focused on products for both companion animals and farm animals. Headquartered in Greenfield, Indiana, it operates globally across pet health and food animal markets.
Elanco develops and markets medicines, vaccines, and preventive treatments for pets and livestock. Revenue comes from selling parasiticides, therapeutics, and nutritional health products through veterinarians, distributors, and farm animal producers including beef, dairy, pork, poultry, and aquaculture operations.
Elanco Animal Health Incorporated was established as an independent public company in 2018 and is headquartered in Greenfield, Indiana.
- Pet parasite prevention (Seresto, Advantage, Advantix, Advocate brands)
- Pet therapeutics for pain, ear infections, and dermatology (Galliprant, Claro brands)
- Farm animal vaccines, antibiotics, and parasiticides (Rumensin, Baytril brands)
- Nutritional health products including enzymes, probiotics, and prebiotics
Is ELAN a Good Stock to Buy?
UQS Score rates ELAN as Poor overall, reflecting weakness across nearly every evaluated dimension.
Valuation is the one area rated Neutral, meaning the stock is not clearly expensive relative to its fundamentals — a modest distinction given the broader profile.
Quality, Moat, Growth, and Risk all carry Weak ratings, signaling meaningful structural and operational challenges that weigh on the investment case.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ELAN pay dividends?
No — Elanco Animal Health Incorporated does not currently pay a dividend.
Elanco does not currently pay a dividend. Given its Weak Quality and Growth pillar ratings, the company appears focused on managing its balance sheet and operational challenges rather than returning capital to shareholders.
When does ELAN report earnings?
Elanco Animal Health reports earnings on a quarterly cadence, typical for US-listed equities.
The company's Weak Growth and Quality pillar ratings suggest earnings results have not demonstrated consistent improvement. Investors should monitor whether management commentary signals any inflection in operational performance.
For the most recent quarter's results, visit Elanco Animal Health's investor relations page directly.
ELAN Price History
-37.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Elanco Animal Health Incorporated?
Based on Elanco Animal Health Incorporated's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Elanco Animal Health do?
Elanco develops, manufactures, and markets health products for pets and farm animals. Its portfolio spans parasite prevention, therapeutics, vaccines, antibiotics, and nutritional health products sold through veterinarians, distributors, and agricultural producers worldwide.
Does ELAN pay dividends?
No, Elanco Animal Health does not currently pay a dividend. The company is not in a position of returning capital to shareholders at this time, given the operational and financial challenges reflected in its UQS pillar ratings.
When does ELAN report earnings?
Elanco reports on a standard quarterly schedule. For confirmed dates and the most recent results, check the investor relations section of Elanco's official website.
Is ELAN a good stock to buy?
UQS Score rates ELAN as Poor, with Weak ratings across Quality, Moat, Growth, and Risk. Only Valuation is Neutral. Investors should weigh these structural concerns carefully before making any decision.
Is ELAN overvalued?
The UQS Valuation pillar for ELAN is rated Neutral, suggesting the stock is not obviously expensive relative to its current fundamentals. However, weak underlying business metrics limit how much comfort that provides.
What is ELAN's market cap bracket?
Elanco Animal Health is classified as a large-cap stock, meaning it carries significant market value despite the operational challenges reflected in its UQS Score.
Is ELAN a long-term quality investment?
As a long-term quality indicator, ELAN's Poor UQS Score — driven by Weak ratings in Quality, Moat, Growth, and Risk — raises meaningful questions about durability. Pro members can access the full analysis to assess whether any pillar shows signs of improvement.
What sector does ELAN belong to?
Elanco Animal Health operates in the Healthcare sector, specifically within animal health — a niche that serves both the companion animal market and food animal production industries globally.
Unlock Full ELAN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare ELAN against sector peers with side-by-side scoring
- ✓Get the complete analyst view available only to Pro members
Pro Analysis
ELAN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 32.7 | 19.8 | 28.0 | 37.1 | 35.6 | 53.4 | -1.0 |
| May 20, 2026 | 33.7 | 20.4 | 28.0 | 37.1 | 35.6 | 58.6 | +1.1 |
| May 13, 2026 | 32.6 | 19.8 | 28.0 | 36.8 | 35.6 | 53.3 | +0.1 |
| May 12, 2026 | 32.5 | 19.8 | 28.0 | 36.8 | 35.6 | 52.0 | +0.1 |
| May 10, 2026 | 32.4 | 5.9 | 28.0 | 36.8 | 37.2 | 72.8 | +0.1 |
| May 8, 2026 | 32.3 | 5.9 | 28.0 | 36.7 | 37.2 | 72.4 | +0.4 |
| May 7, 2026 | 31.9 | 19.1 | 28.0 | 36.7 | 35.6 | 49.5 | +0.9 |
| May 3, 2026 | 31.0 | 15.8 | 28.0 | 35.9 | 35.0 | 50.5 | +0.1 |
| May 2, 2026 | 30.9 | 15.8 | 28.0 | 35.9 | 35.0 | 50.1 | 0.0 |
| Apr 26, 2026 | 30.9 | 15.8 | 28.0 | 36.0 | 35.0 | 50.1 | +0.2 |
ELAN — Pillar Breakdown
Quality
— 19.8/100 (25%)Elanco Animal Health Incorporated currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 37.1/100 (20%)Elanco Animal Health Incorporated shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 35.6/100 (15%)Elanco Animal Health Incorporated has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 53.7/100 (15%)Elanco Animal Health Incorporated has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 28/100 (25%)Elanco Animal Health Incorporated operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ELAN.
Score Composition
Financial Data
More Stock Analysis
How is the ELAN UQS Score Calculated?
The UQS (Unified Quality Score) for Elanco Animal Health Incorporated is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Elanco Animal Health Incorporated's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Elanco Animal Health Incorporated is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.